AI Article Synopsis
- - This study evaluates the combination of regorafenib and toripalimab in treating colorectal cancer, showing an objective response rate (ORR) of 15.2% and a disease control rate of 36.4% at the recommended phase II dose.
- - Median progression-free survival (PFS) is 2.1 months and overall survival is 15.5 months, with lower response rates in patients with liver metastases compared to those without (8.7% vs. 30.0%).
- - Adverse events were common, with 94.9% of patients experiencing grade 1 and 38.5% grade 3 complications, and gut microbiome analysis suggests that higher abundance
Article Abstract
This is a phase Ib/II study of regorafenib plus toripalimab for colorectal cancer. The objective response rate (ORR) is 15.2% and the disease control rate is 36.4% in evaluable patients with recommended phase II dose (80 mg regorafenib plus toripalimab). The median progression-free survival (PFS) and the median overall survival are 2.1 months and 15.5 months, respectively. Patients with liver metastases have lower ORR than those without (8.7% versus 30.0%). All patients (3/3) with lung-only metastasis respond, whereas no patients (0/4) with liver-only metastasis respond. 94.9% and 38.5% of patients have grade 1 and grade 3 treatment-related adverse events, respectively. Gut microbiome analysis of the baseline fecal samples shows significantly increased relative abundance and positive detection rate of in non-responders than responders. Patients with high-abundance have shorter PFS than those with low abundance (median PFS = 2.0 versus 5.2 months; p = 0.002).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484502 | PMC |
| http://dx.doi.org/10.1016/j.xcrm.2021.100383 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regorafenib alone or in combination with high/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer: protocol for a prospective, randomized, controlled phase II clinical trial (SLOT).
Front Oncol
October 2023
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Article Synopsis
- The study focuses on improving treatment responses in microsatellite stable metastatic colorectal cancer (MSS mCRC) by exploring the combination of regorafenib, radiotherapy, and toripalimab after some promising but inconsistent results from previous trials.
- It involves a randomized controlled phase II trial comparing a control group receiving only regorafenib with an experimental group receiving regorafenib, toripalimab, and both high and low-dose radiotherapy.
- Key goals include determining objective response rates and other effectiveness measures, with patient recruitment having started in August 2023.
Article Synopsis
- Rui-Hua Xu conducted the REGOTORI trial, which revealed that a combination of regorafenib and toripalimab enhances the effectiveness and survival rates in patients with refractory metastatic colorectal cancer.
- The trial also identified that high levels of certain biomarkers were linked to poorer responses and survival outcomes.
- In a Q&A, Xu shares insights about his academic path and outlines potential future developments in cancer research.
Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report.
World J Clin Cases
April 2022
Department of Dermatology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China.
Article Synopsis
- A case report highlights a 39-year-old male who developed toxic epidermal necrolysis (TEN) after combination therapy with the PD-1 inhibitor toripalimab and lenvatinib, showing serious skin reactions affecting over 70% of his body.
- Histological examination revealed severe skin damage, while the patient was previously battling liver cancer with metastasis; the treatment included high-dose corticosteroids and immunoglobulin.
- The report emphasizes the need for careful monitoring of skin rashes during this combination therapy, as timely intervention with glucocorticoids can be critical for managing TEN.
Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis.
Cell Rep Med
September 2021
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
Article Synopsis
- - This study evaluates the combination of regorafenib and toripalimab in treating colorectal cancer, showing an objective response rate (ORR) of 15.2% and a disease control rate of 36.4% at the recommended phase II dose.
- - Median progression-free survival (PFS) is 2.1 months and overall survival is 15.5 months, with lower response rates in patients with liver metastases compared to those without (8.7% vs. 30.0%).
- - Adverse events were common, with 94.9% of patients experiencing grade 1 and 38.5% grade 3 complications, and gut microbiome analysis suggests that higher abundance
Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.
J Oncol
September 2021
Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Article Synopsis
- The study investigates the combined use of regorafenib, a tyrosine kinase inhibitor, and toripalimab, an anti-PD-1 monoclonal antibody, for treating advanced colorectal cancer, particularly in microsatellite stable (MSS) patients who typically do not respond well to immune therapies.
- The research involved 33 MSS patients who had undergone at least two prior treatments, receiving regorafenib and toripalimab until disease progression or intolerable side effects.
- Key metrics assessed included the objective remission rate, disease control rate, median progression-free survival, and the occurrence of any adverse reactions associated with the treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!